Sulfasalazine, a FDA-approved drug for rheumatoid arthritis or inflammatory bowel disease with chronic inflammation, is an ATP-competitive inhibitor of IKKβ activity, and BMS 345541 is an allosteric inhibitor21, 22. Here, IKBKB is linked to inflammatory bowel disease.